djokovic1

Thanks!

Thanks! The article was a pretty good summary actually though it missed that I recommended 2 books not one, and stressed that @Viking's compendium is a must read for anyone who wants to learn deeply about Fairfax.

Pitched Fairfax at a Value Investing Conference in Italy last week. Got picked up by Bloomberg (attached). Will share slides and video if interesting. VIS Bridgewater Vet Pitches_BBG_Article_Fairfax.pdf

Can you use that framework to estimate what Fairfax’s multiple will be in five years?

The bank is essentially renting out leveraged economic exposure to FFH shares to Fairfax. It earns the floating rate on the notional (its “spread” above its own cost of funds is its profit), while being neutral on the share price because it hedges by holding the physical shares. The bank takes on counterparty credit risk against Fairfax (mitigated by collateral) and liquidity/execution risk in managing the hedge, but has no directional view on FFH’s stock price.

yes 100% agreed in the short term. But the supply demand view will give ‘no’ real information on what the multiple will be in 3-5 years. Which is what I am solving for and I believe that multiple is much more likely to be driven by fundamental value with that time horizon. which ties into the buffet quote..voting machine short term, weighing machine long term

maybe, maybe not. We can try to rationalize it in hindsight. The true test is if you can predict when it happens ex ante. I would suggest that’s impossible. for example consensus was Fairfax added to TSX will lead to multiple expansion but that didn’t happen

Terravest: Flat multiple for many years below 10x and then boom. Lindbergh, Sygnity, NGTG, Tasmea, Chapters group

This post might not age well (or it may!) but when multiple expansion happens it usually happens rapidly and when people least expect it. And there isn’t necessarily a reason you can clearly point to even with hindsight. I have seen it multiple times. It’s just price matching up with value (the only law in investing) . We just don’t know if it will happen next month or in 5 years. With buybacks we can (mostly) sit back and relax regardless.

Personally, I think 2x+ book or 15x P/E+ is roughly right. Based on first principles. Using relative valuation of other insurers as a reference, even that might be low. I don’t spend much time at all thinking about what multiple the market will assign my stocks. (This only works if the business understands capital allocation and their own intrinsic value and aggressively repurchases share if they are mispriced)

I am not so sure about this. Markel breaks down their equity returns pretty clearly, the below is from 2025. The 20 year return is pretty good but based on my calculations Fairfax has done better, ~15% CAGR including the negative impact of hedging and positive impact of CDS and TRS. I include all those elements because they are all active decisions taken which either add or detract from alpha.

Agreed. In general the clarity of thought w.r.t capital allocation and compounding is much higher at Berkshire (of course) and Fairfax.

They have mentioned it but definitely less than BRK and FFH. The Q1 2010 earnings calls has specific commentary in the Q&A on float growth, leverage, and equity allocation and its worth reading. Generally they have prioritised a higher allocation of equities in the book than higher investment leverage. They will do better than Fairfax in a zero interest rate environment all else equal but Fairfax is much better positioned in the current environment. Here are some of the instances using AI re their mention of float: 1. Status update presentation — "More float, more earnings power" Andrew Crowley (President of Markel Ventures) explicitly tied float growth to earnings power compounding: > "During the same timeframe, operating cash flows exceeded operating income by $5 billion, mostly due to the power of increasing insurance float. More float, more earnings power." The accompanying investor presentation slide also frames growth in float as one of several distinct levers for increasing earnings per share over time, alongside Markel Ventures, public equities, and share repurchases. 2. Q3 2023 earnings call — maximising investment return on float Jeremy Noble (President of Insurance): > "The insurance engine also continues to generate significant operating cash flows, and we have been intentional about taking the cash and maximizing the investment return on the float generated by our underwriting operations and attractive market yields." 3. Q1 2022 earnings call — the float spread as the core economic model Richie Whitt (Co-CEO) articulated the fundamental spread model clearly: > "We're making a spread of return between the positive yields on the bond portfolio and the negative cost of float that we get through underwriting profitability. And as long as we keep that spread a positive number, things add up to the good over time."

@SafetyinNumbers I love this chart. It shows how much more resilient Fairfax is today relative to its history to Cats. Shareholder equity has grown faster than premiums over the past 20 years. Since 2005: Shareholder equity 10x: $2.4bn -> $26bn Premiums 6x: $5bn -> $30bn. Same for float $6.6 ->$40. This is an additional reason that explains the widening gap and buffer i.e shareholder equity has grown faster than premiums/float. (interestingly buybacks will have the effect of reducing this buffer but of course increase per share value). The other aspect is that Fairfax will have 1-2% exposure to any Global catastrophe based on its size. There isn't idiosyncratic exposure as cat risk is shared across insurers. This is the latest one (a bit hazy) from the 2025 sustainability report.

My personal opinion is there is a big difference between Fairfax and Fairfax India. 2 big ones. 1) Fairfax doesn’t need great equity investments to be a great investment. A mediocre equity performance there will lead to a more than satisfactory result ie 15%+ because of the float/investment leverage and locked in income streams. Fairfax India doesn’t have that. It’s an investment vehicle and its performance is directly correlated to its equity investments and at this point majority of it is linked to Bial. If you look 10 years out you have to trust their investment acumen much more than you have to do for Fairfax. 2) Fairfax can solve its own problems re low valuation by buying back its own shares. Fairfax India cannot do this as its cashflow poor ie its an investment vehicle. This is a major disadvantage. For Fairfax India you have to rely on a multiple rerate which again is most likely dependent on BIAL and its IPO and that will be a one time uplift. A third one is with Fairfax India you are always fighting against the headwind of currency depreciation. So structurally there are big differences. Of course I am rooting for Fairfax India but for me the investment case is much clearer for one than the other.